Updated Results from Phase 1 Study of Telaglenastat (CB-839) to be Presented at 2019 ASCO Genitourinary Cancer Symposium

February 16, 2019

We're not around right now. But you can send us an email and we'll get back to you, asap.

Start typing and press Enter to search